After the first dose being administered on July 31, all four volunteers showed nor reactions and the trials have begun on expected lines
The much-awaited trial of BBV152 COVID-19 vaccine or Covaxin commenced at the Institute of Medical Sciences and SUM Hospital, one of the 12 centres selected by Indian Council of Medical Research (ICMR) for conducting phase one and two of the process, the official at the facility said.
With over 1.5 crore people across the globe having contracted the infection, the world is eagerly awaiting a vaccine that would bolster the global fight against COVID-19.
Already, over 3,500 volunteers have registered themselves for the trial at AIIMS since last Saturday, of whom the screening of at least 22 people is underway, said Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS and the principal investigator of the study.
In the first stage of clinical trials, healthy participants between 18 and 55 years of age, with no comorbidities and without a history of COVID-19, will be selected.
COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently received the nod for human clinical trials from the Drugs Controller General of India (DCGI).
The volunteers ought to be aged between 18 and 55 years and should not have any comorbidities. To participate, they would have to send an email to email@example.com or send an SMS to 7428847499 or call 7428847499.
The Drug Controller General of India recently granted permission to initiate Phase I & II human clinical trials for COVID-19 Vaccine COVAXIN.
Clinical trials of the indigenous COVID-19 COVAXIN may be delayed further as multiple institutes, which are selected to hold these trials, still evaluating the process.
The article has been published on the websites of the Press Information Bureau (PIB) and the Vigyan Prasar, which is a body under the ministry.
This is as per a letter written as internal communication by ICMR to Bharat Biotech asking for fast-tracking of the indigenous vaccine with an aim to launch by August 15.
The inactivated vaccine has shown promise in preclinical studies, demonstrating extensive safety and effective immune responses.